<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514108</url>
  </required_header>
  <id_info>
    <org_study_id>DANHEART</org_study_id>
    <secondary_id>2015-002150-12</secondary_id>
    <nct_id>NCT03514108</nct_id>
  </id_info>
  <brief_title>DANHEART (H-HeFT and Met-HeFT)</brief_title>
  <acronym>DANHEART</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Wiggers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Council for Independent Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Regions: Foundation for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Novo Nordisk Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Aase og Ejnar Danielsen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is testing in a combined design to types of drugs in patients with chronic
      heart failure: 1) Hydralazine in combination with isosorbide dinitrate (BiDil) and 2)
      Metformin hydrochloride. The study is double blind, placebo controlled.

        1. The first hypothesis is that hydralazine in combination with isosorbide dinitrate can
           reduce mortality and hospitalization with worsening heart failure.

        2. The second hypothesis is that treatment of underlying insulin resistance/ type 2
           diabetes with metformin in heart failure patients with moderately to severely reduced
           LVEF can reduce mortality and cardiovascular hospitalizations. Among secondary endpoints
           are reduction in new-onset diabetes in heart failure patients with insulin resistance
           and diabetes risk profile and patient safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Patients can be allocated to either
both Hydralazine Isosorbide Dinitrate / Placebo and Metformin hydrochloride / Placebo
to only Hydralazine Isosorbide Dinitrate / Placebo.
to only Metformin hydrochloride / Placebo.
Patient characteristics are entered in an electronic CRF. According to in- and exclusion criteria they are randomized in three blocks:
Patients receiving both Hydralazine Isosorbide Dinitrate / Placebo and Metformin hydrochloride / Placebo
Patients receiving only Hydralazine Isosorbide Dinitrate / Placebo and
Patients receiving only Metformin hydrochloride / Placebo
Analysis will be performed in:
all patients who have received Hydralazine Isosorbide Dinitrate / Placebo (H-HeFT) and
all patients who have received Metformin hydrochloride / Placebo (Met-HeFT)
The study is event driven. Anticipated: both H-HeFT and Met-HeFT 900, only H-HeFT 400, only Met-HeFT 200 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H-HeFT combined endpoint: Death or hospitalization with worsening heart failure.</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Death or hospitalization with worsening heart failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Met-HeFT combined endpoint: Death or hospitalization with worsening heart failure or acute myocardial infarction or stroke</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Death or hospitalization with worsening heart failure or acute myocardial infarction or stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>H-HeFT secondary endpoint: Death</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H-HeFT secondary endpoint: Hospitalization with worsening heart failure</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Hospitalization with worsening heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H-HeFT secondary endpoint: Combined endpoint: Death or cardiovascular hospitalizations (hospitalization with worsening heart failure, acute myocardial infarction, or stroke)</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Combined endpoint: Death or cardiovascular hospitalizations (hospitalization with worsening heart failure, acute myocardial infarction, or stroke)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Met-HeFT secondary endpoint: Extended clinical endpoint: The primary endpoint or coronary revascularization or non-coronary revascularization or limb amputation.</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Extended clinical endpoint: The primary endpoint or coronary revascularization or non-coronary revascularization or limb amputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Met-HeFT secondary endpoint: Death</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Met-HeFT secondary endpoint: Hospitalization with worsening heart failure</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Hospitalization with worsening heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Met-HeFT secondary endpoint: Acute myocardial infarction</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Met-HeFT secondary endpoint: Stroke</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Met-HeFT secondary endpoint: New onset type 2 diabetes</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>New onset type 2 diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Met-HeFT secondary endpoint: Hospitalization or death caused by lactate acidosis.</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Hospitalization or death caused by lactate acidosis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Hydralazine Isosorbide Dinitrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablet BiDil (Hydralazine 37.5 mg/ isosorbide dinitrate (ISDN) 20 mg) 2 tablets x 3 daily.
Average treatment period 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Hydralazine Isosorbide Dinitrate)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet Placebo 2 tablets x 3 daily. Average treatment period 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Metformin)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet Placebo 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydralazine Isosorbide Dinitrate</intervention_name>
    <description>Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily</description>
    <arm_group_label>Hydralazine Isosorbide Dinitrate</arm_group_label>
    <other_name>BiDil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>2 tablets x 3 daily</description>
    <arm_group_label>Placebo (Hydralazine Isosorbide Dinitrate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)</description>
    <arm_group_label>Placebo (Metformin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General inclusion criteria for both H-HeFT and Met-HeFT

          -  Patients with chronic heart failure

          -  NYHA-class II, III or IV

          -  LVEF &lt;/= 40% within 12 months prior to screening. The echocardiography should (i) be
             performed after uptitration in heart failure medication and (ii) LVEF from the most
             recently performed echocardiographic study should be used and (iii) LVEF must not be
             measured during rapid atrial fibrillation, i.e. heart rate &gt;110/min) and (iiii) the
             echocardiography should be performed at least 3 months after CRT-implantation.

          -  Patients should be uptitrated to recommended or maximally tolerated dose of
             ACE-I/ARB/ARNI (unless contraindicated) and beta-blocker (unless contraindicated). If
             indicated, an aldosterone receptor antagonist should be given (unless
             contraindicated).

          -  A CRT device should be implanted, if indicated and accepted by the patient and
             patients with a CRT device should be treated for &gt; 3 months.

          -  Implantation of an ICD unit should be planned or already done, if indicated and
             accepted by the patient. The patient can be included in the study before a planned ICD
             implantation has been performed.

          -  Informed consent

        Specific inclusion criteria for only H-HeFT:

          -  Systolic blood pressure ≥100 mmHg

          -  NT-proBNP &gt; 350 pg/ml or BNP &gt; 80 pg/ml (in patients treated with ARNI, NT-proBNP must
             be used)

        Specific inclusion criteria for only Met-HeFT:

        Patients must have a diagnosis of type 2 diabetes or insulin resistance or diabetes risk.
        This includes 1 or more of any of the following:

          -  A previous diagnosis of type 2 diabetes at any time without Metformin treatment during
             the last 3 months

          -  HbA1c ≥ 5.5 % (≥ 37 mmol/mol) within 12 months prior to screening

          -  Fasting P-glucose ≥ 5.6 mmol/l within 12 months prior to screening (measured when the
             patient in stable condition / has no intercurrent illness)

          -  Body mass index ≥ 30 kg/m2

          -  If oral glucose tolerance testing (OGTT) has been performed at any time prior to
             randomization: 2 hour P-glucose ≥ 7.8 mmol/l

          -  In addition, patients in Met-HeFT must have eGFR ≥ 35 ml/min (MDRD)

        Patients are randomized through an internet based randomization module. Patients can be
        allocated to a) both H-HeFT and Met-HeFT or to b) only H-HeFT or to c) only Met-HeFT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Wiggers, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Cardiology, Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Køber, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Cardiology, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Finn Gustafsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology, Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren Mellemkjaer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology, Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar Gislason, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Danish Heart Foundation, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Wiggers, MD, PhD</last_name>
    <phone>+45 40136627</phone>
    <email>henrikwiggers@dadlnet.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sygehus Sønderjylland, Aabenraa</name>
      <address>
        <city>Aabenraa</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bartlomiej Jonczy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Søren Vraa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Wiggers</last_name>
      <phone>+45 40136627</phone>
      <email>henrikwiggers@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Anders Jorsal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amager Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margrethe Ege Olsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olav Wendelbo Nielsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Schou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten Petersen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Schou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Hove</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Køber</last_name>
    </contact>
    <investigator>
      <last_name>Finn Gustafsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus, Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Vilain Mikkelsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten Bøttcher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionshospital Nordjylland, Hjørring</name>
      <address>
        <city>Hjørring</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gitte Nielsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horsens Hospital</name>
      <address>
        <city>Horsens</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Kaae Dodt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Petronela Poenaru</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nykøbing Falster Hospital</name>
      <address>
        <city>Nykøbing Falster</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisbeth Tingsted</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikael Kjær Poulsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sjællands Universitetshospital, Roskilde</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nina Pernille Gardshodn Buch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silkeborg Hospital</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Frost</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Slagelse Sygehus</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Ryde</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vibeke Brogaard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Pauline Schrøder</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Wiggers</investigator_full_name>
    <investigator_title>Consultant, Associate professor, MD, PhD, DMSc</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Metformin</keyword>
  <keyword>Hydralazine</keyword>
  <keyword>Isosorbide Dinitrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Hydralazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

